Buprenorphine exposure in infants of opioid-dependent mothers at birth

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 52, Issue 4, 2012, Pages 342-347

  Bartu, Anne E ^a   Ilett, Kenneth F ^b,c   Hackett, L Peter ^c   Doherty, Dorota A ^d   Hamilton, Dale ^e  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Path West Laboratory Medicine   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e King Edward Memorial Hospital Women and Newborn Health Services   (Australia)

Author keywords

buprenorphine; infant exposure at delivery; norbuprenorphine; placental transfer

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; BIRTH WEIGHT; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MATERNAL SERUM; NEWBORN; NEWBORN INTENSIVE CARE; OPIATE ADDICTION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; UMBILICAL CORD BLOOD; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; AUSTRALIA; BUPRENORPHINE; CHROMATOGRAPHY, LIQUID; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; LINEAR MODELS; MATERNAL-FETAL EXCHANGE; MOTHERS; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; TANDEM MASS SPECTROMETRY;

EID: 84864676902     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2012.01424.x     Document Type: Article

References (30)

1. Lintzeris N, Clark N, Muhleisen P, et al,. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. Canberra, Australia: Department of Health and Ageing, Commonwealth of Australia, 2001.
2. Elkader A, Sproule B,. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44 (7): 661-680.
3. Schindler SD, Eder H, Ortner R, et al,. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003; 98 (1): 103-110.
4. Johnson RE, Jones HE, Fischer G,. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 70 (2 Suppl): S87-S101.
5. Jones HE, Kaltenbach K, Heil SH, et al,. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363 (24): 2320-2331.
6. Colombini N, Elias R, Busuttil M, et al,. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone. Pharm World Sci 2008; 30 (3): 227-234.
7. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S,. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82 (3): 250-257.
8. Fischer G, Ortner R, Rohrmeister K, et al,. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101 (2): 275-281.
9. Anonymous. Psychotropic drugs. In:, Rossi S, ed. The Australian Medicines Handbook. Adelaide, Australia: The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, the Pharmaceutical Society of Australia and the Royal Australian College of General Practitioners, 2011: 786-787.
10. Anonymous. General Information on Drug Use in Pregnancy: Psychotropic Drugs; Drugs For Opioid Dependence. Electronic Therapeutic Guidelines Complete. [Accessed 23 February 2012.] Available from URL: http://www.tg.org.au. West Melbourne, Australia: Therapeutic Guidelines Limited, 2011.
11. Iribarne C, Picart D, Dreano Y, et al,. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60 (22): 1953-1964.
12. Rios GR, Tephly TR,. Inhibition and active sites of UDP- glucuronosyltransferases 2B7 and 1A1. Drug Metab Dispos 2002; 30 (12): 1364-1367.
13. King CD, Green MD, Rios GR, et al,. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP- glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332 (1): 92-100.
14. Rouguieg K, Picard N, Sauvage FL, et al,. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38 (1): 40-45.
15. Deshmukh SV, Nanovskaya TN, Ahmed MS,. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther 2003; 306 (3): 1099-1105.
16. Collier AC, Ganley NA, Tingle MD, et al,. UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol 2002; 63 (3): 409-419.
17. Concheiro M, Jones HE, Johnson RE, et al,. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit 2010; 32 (2): 206-215.
18. Ohtani M, Kotaki H, Sawada Y, Iga T,. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272 (2): 505-510.
19. Ohtani M, Kotaki H, Nishitateno K, et al,. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281 (1): 428-433.
20. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS,. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002; 300 (1): 26-33.
21. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, et al,. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem Pharmacol 2009; 78 (9): 1272-1278.
22. Gordon AL, Lopatko OV, Somogyi AA, et al,. (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. Br J Clin Pharmacol 2010; 70 (6): 895-902.
23. Finnegan LP, Kaltenbach K,. Neonatal abstinence syndrome. In:, Hoekelman RA, Friedman SB, Nelson N, Seidel HM, eds. Primary pediatric care, 2nd edn. St Louis, USA: CV Mosby, 1992; 1367-1378.
24. Grimm D, Pauly E, Poschl J, et al,. Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005; 27 (4): 526-530.
25. Bolton S,. Transformations and outliers. Pharmaceutical statistics; practical and clinical applications. New York and Basel: Marcel Dekker Inc, 1984; 281-300.
26. Kakko J, Heilig M, Sarman I,. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96 (1-2): 69-78.
27. Johnson RE, Jones HE, Jasinski DR, et al,. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001; 63 (1): 97-103.
28. Marquet P, Chevrel J, Lavignasse P, et al,. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997; 62 (5): 569-571.
29. Concheiro M, Jones H, Johnson RE, et al,. Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878 (1): 13-20.
30. Concheiro M, Jones HE, Johnson RE, et al,. Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. J Anal Toxicol 2010; 34 (8): 498-505.